Mollugin

Research use only, not for human use.

Mollugin may be a JAK2 inhibitor and inhibits LPS-induced inflammatory responses by blocking the activation of the JAK-STAT pathway.

Mollugin may be a JAK2 inhibitor and inhibits LPS-induced inflammatory responses by blocking the activation of the JAK-STAT pathway. Mollugin as a candidate for a chemotherapeutic agent in OSCCs via the upregulation of the HO-1 and Nrf2 pathways and the downregulation of NF- κ B. Mollugin may be a novel therapeutic candidate for bone loss-associated disorders including osteoporosis, rheumatoid arthritis, and periodontitis. Also, it has anticancer efficacy, can modulate the HER2 pathway in HER2-overexpressing Y cells with a potential role in the treatment and prevention of human breast and ovarian Y with HER2 overexpression.

Mollugin (0-80 μM, 24 h) inhibits the expression of an NF-κB reporter gene induced by TNF-α in a dose-dependent manner.Mollugin (0-80 μM, 12 h) inhibits the proliferation of HeLa cells.Mollugin (0-80 μM, 12 h) inhibits TNF-α-induced phosphorylation and nuclear translocation of p65, phosphorylation and degradation of IκBα, and IKK phosphorylation, and inhibits the TNF-α-induced mRNA expression of Cyclin D1, c-Myc, and VEGF. Mollugin (0-80 μM, 12 h) enhances TNF-α-induced apoptosis. Cell Viability Assay Cell Line:HeLa, Hep3B, and HEK293 cells Concentration:0, 10, 20, 40, and 80 μM Incubation Time:24 h Result:Significantly inhibited NF-κB reporter gene expression in a dose-dependent manner, did not display significant cellular toxicity in HeLa, Hep3B, and HEK293 cells.Cell Proliferation Assay Cell Line:HeLa cells Concentration:0, 20, 40, and 80 μM Incubation Time:12 h Result:Inhibited the proliferation of HeLa cells. Apoptosis Analysis Cell Line:HeLa cellsConcentration:0, 10, 20, 40, and 80 μM Incubation Time:12 hResult:Slightly affected the caspase-3 activation, potentiated the effect of TNF-α-induced PARP cleavage, and enhanced the apoptotic effects of TNF-α.Western Blot Analysis Cell Line:HeLa cells Concentration:0, 10, 20, 40, and 80 μM Incubation Time:12 h Result:Significantly inhibited the TNF-α-induced p65 phosphorylation and block TNF-α-induced nuclear translocation of p65 in a dose-dependent manner, completely inhibited degradation of IκBα at 80 μM, and abolished the TNF-α-induced IKK phosphorylation at 80 μM. Inhibited the TNF-α-induced mRNA expression of Cyclin D1, c-Myc, and VEGF at 80 μM.

Mollugin (0-75 mg/kg, Orally, three times per week for 36 days) inhibits growth of HeLa cells in a xenograft tumor model. Animal Model:BALB/c female athymic nude mice (six-week-old, subcutaneously injected with 0.2 mL HeLa cells)Dosage:0, 25 and 75 mg/kg Administration:Orally, three times per week for 36 days Result:Suppressed tumor growth, whereas the body weight did not change. Significantly reduced the protein expression of p-p65 and COX-2 in the tumors.

Rubimaillin | Mollugin

Chromatin/Epigenetic

COX

HER2| JAK2

Others-Field

——

55481-88-4

284.3

C17H16O4

>98% (HPLC)

In Vitro:?DMSO : 33.33 mg/mL (117.23 mM)

CC1(C=Cc2c(O1)c1ccccc1c(c2C(=O)OC)O)C

methyl 6-hydroxy-2,2-dimethyl-2H-benzo[h]chromene-5-carboxylate

(-20℃)

With Ice Pack

≥ 2 years